# Modulating innate immune cells in the tumor microenvironment of pancreas cancer to enhance anti-tumor immunity

> **NIH NIH R01** · UNIVERSITY OF ROCHESTER · 2020 · $351,098

## Abstract

PROJECT SUMMARY/ABSTRACT
A Phase 1b clinical trial of dual myeloid blockade in metastatic pancreatic adenocarcinoma (PDAC) is planned.
Patients will be treated with standard chemotherapy (FOLFIRINOX) and 2 orally available, small molecule
allosteric chemokine receptor inhibitors to CCR2 (CXC872) and CXCR1/2 (SX682). The primary endpoint of
the trial is safety and tolerability, and the secondary endpoint is clinical effectiveness as measured by
progression free survival at 24 weeks. Baseline and on treatment tumor biopsies will be subjected to genomic
analysis as well as sophisticated immune monitoring using mass cytometry. Genetic and immunologic
biomarkers of treatment resistance and response will be explored. Preclinical studies will also be performed
throughout the study to inform and perfect subsequent clinical translation of the most effective ways to
immunologically reprogram the immunosuppressive tumor microenvironment that is characteristic of PDAC.

## Key facts

- **NIH application ID:** 9840875
- **Project number:** 5R01CA168863-07
- **Recipient organization:** UNIVERSITY OF ROCHESTER
- **Principal Investigator:** DAVID C LINEHAN
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $351,098
- **Award type:** 5
- **Project period:** 2013-07-01 → 2023-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9840875

## Citation

> US National Institutes of Health, RePORTER application 9840875, Modulating innate immune cells in the tumor microenvironment of pancreas cancer to enhance anti-tumor immunity (5R01CA168863-07). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9840875. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*